Payment overview · 2025
General Payments
$181.27
10 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Stephen Tucker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1205829710
Verified facts
What the public records show
CMS Open Payments records show Robert Stephen Tucker, M.D. received $181.27 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.69 | 49.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.92 | 33.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.86 | 8.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.80 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.27 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.42 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.92 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.92 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.63 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 979 | 234 |
| Levothyroxine Sodium | Levothyroxine Sodium | 815 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 679 | 170 |
| Losartan Potassium | Losartan Potassium | 665 | 172 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 550 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 468 | 121 |
| Clonazepam | Clonazepam | 396 | 73 |
| Omeprazole | Omeprazole | 393 | 119 |
| Diclofenac Sodium | Diclofenac Sodium | 349 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 342 | 87 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 316 | 86 |
| Meloxicam | Meloxicam | 302 | 121 |
| Tizanidine Hcl | Tizanidine Hcl | 293 | 108 |
| Escitalopram Oxalate | Escitalopram Oxalate | 290 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 286 | 76 |
| Simvastatin | Simvastatin | 264 | 61 |
| Metformin Hcl | Metformin Hcl | 261 | 66 |
| Furosemide | Furosemide | 251 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 61 |
| Trazodone Hcl | Trazodone Hcl | 243 | 66 |
| Metformin Hcl Er | Metformin Hcl | 239 | 62 |
| Lisinopril | Lisinopril | 231 | 64 |
| Gabapentin | Gabapentin | 218 | 60 |
| Allopurinol | Allopurinol | 207 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 50 |
| Ozempic | Semaglutide | 189 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 166 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 42 |
| Montelukast Sodium | Montelukast Sodium | 159 | 45 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 145 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 37 |
| Raloxifene Hcl | Raloxifene Hcl | 120 | 24 |
| Bupropion Xl | Bupropion Hcl | 116 | 26 |
| Potassium Chloride | Potassium Chloride | 112 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 111 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 31 |
| Prednisone | Prednisone | 103 | 82 |
| Eliquis | Apixaban | 101 | 23 |
| Donepezil Hcl | Donepezil Hcl | 94 | 18 |
| Doxepin Hcl | Doxepin Hcl | 89 | 27 |
| Estradiol | Estradiol | 89 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 23 |
| Azithromycin | Azithromycin | 88 | 79 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 28 |
| Mirtazapine | Mirtazapine | 86 | 29 |
| Benazepril Hcl | Benazepril Hcl | 84 | 21 |
| Sertraline Hcl | Sertraline Hcl | 83 | 22 |
| Carvedilol | Carvedilol | 81 | 24 |
| Jardiance | Empagliflozin | 75 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 72 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 16 |
| Synthroid | Levothyroxine Sodium | 68 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 35 |
| Spironolactone | Spironolactone | 64 | 22 |
| Finasteride | Finasteride | 62 | 13 |
| Valacyclovir | Valacyclovir Hcl | 62 | 27 |
| Pregabalin | Pregabalin | 61 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 59 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 43 |
| Telmisartan | Telmisartan | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 13 |
| Verapamil Er | Verapamil Hcl | 46 | suppressed |
| Mupirocin | Mupirocin | 45 | 35 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 39 |
| Amoxicillin | Amoxicillin | 43 | 42 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 16 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Atenolol | Atenolol | 38 | 14 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 31 |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 16 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 19 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Diazepam | Diazepam | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.27 · 10 records | ABBVIE INC. | AIRSUPRA, ELIQUIS, MOUNJARO, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error